ArticleJournal of translational medicine2026
Research on the mechanism of CRMP4-mediated cytoskeletal actin polymerization in promoting invasive migration of stromal cells in endometriosis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEndometriosis (EMs) is often classified as a benign disease; however, it exhibits malignant biological characteristics. Collapsin Response Mediator Protein 4 (CRMP4) has been implicated in the regulation of cell migration and invasion via its effects on the cytoskeleton, but its role in EMs remains unclear. This study investigates the role of CRMP4 in the pathogenesis of endometriosis, particularly in ectopic endometrial stromal cells (EcESCs).
methodsWe utilized a human endometrial ectopic stromal cell line (ihESCs), primary eutopic(Eu-ESCs), ectopic(Ec-ESCs) and control(CON-EuESCs) endometrial stromal cells, plus clinical samples. CRMP4 expression was disrupted with siRNA or lentiviral vectors; phenotypic changes were assessed by Transwell and wound-healing assays. A free-actin detection kit quantified polymerization and depolymerization. Stable ihESC cell lines overexpressing or knockout CRMP4 were analyzed by immunofluorescence, Western blot, and qPCR for MRTF/SRF axis activity after actin-modulating drugs. An in vivo mouse model received CRMP4-silencing lentivirus to evaluate lesion size and number; MRTF/SRF levels were examined by IHC, IF, WB and qRT-PCR.
resultsCRMP4 expression was significantly elevated in EcESCs and correlated positively with ASRM staging. CRMP4 promoted the polymerization of free actin, enhancing motility and invasiveness of endometrial stromal cells. It facilitated the nuclear translocation of MRTF, activating SRF and increasing the expression of downstream target genes related to migration and invasion. Targeting CRMP4 inhibited the growth of endometriosis lesions.
conclusionCRMP4 critically promotes actin polymerization and the invasive behaviors of ectopic mesenchymal cells in endometriosis by activating the MRTF/SRF axis. Targeting CRMP4 offers a promising therapeutic and diagnostic strategy for endometriosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.